Ipsen (FR:IPN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ipsen’s Iqirvo (elafibranor) shows promising long-term efficacy and safety in treating primary biliary cholangitis (PBC), with significant improvements in symptoms such as fatigue and pruritus over three years. The data, presented at the AASLD congress, bolsters Iqirvo’s potential as a leading treatment choice for PBC, having been approved in several major markets in 2024.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.